Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carla Casulo

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Blood Advances|January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaDanielle S Wallace, Clive S Zent, Andrea M Baran, et al.
JACC. Advances|June 28, 2024
Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of LymphomaAmole Ojo, Ilan Goldenberg, Scott McNitt, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 15, 2022
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM StudyCarla Casulo, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Geriatric Oncology|March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailtyPatrick M Reagan, Allison Magnuson, Craig A Portell, et al.
Journal of Adolescent and Young Adult Oncology|September 3, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort StudyJohn Mariano, Myla Strawderman, Eric Snyder, et al.
Leukemia & Lymphoma|October 26, 2020
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphomaThomas D Rodgers, AnnaLynn M Williams, Andrea Baran, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center ExperienceAnnaLynn M Williams, Andrea M Baran, Carla Casulo, et al.
Experimental Hematology|December 3, 2014
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approachMichelle Kiebala, Jolanta Skalska, Carla Casulo, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Blood Advances|January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaDanielle S Wallace, Clive S Zent, Andrea M Baran, et al.
JACC. Advances|June 28, 2024
Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of LymphomaAmole Ojo, Ilan Goldenberg, Scott McNitt, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 15, 2022
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM StudyCarla Casulo, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Geriatric Oncology|March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailtyPatrick M Reagan, Allison Magnuson, Craig A Portell, et al.
Journal of Adolescent and Young Adult Oncology|September 3, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort StudyJohn Mariano, Myla Strawderman, Eric Snyder, et al.
Leukemia & Lymphoma|October 26, 2020
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphomaThomas D Rodgers, AnnaLynn M Williams, Andrea Baran, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center ExperienceAnnaLynn M Williams, Andrea M Baran, Carla Casulo, et al.
Experimental Hematology|December 3, 2014
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approachMichelle Kiebala, Jolanta Skalska, Carla Casulo, et al.
Pageof 9